The UK market has recently faced challenges, with the FTSE 100 index faltering due to weak trade data from China, highlighting global economic interdependencies. Amid such fluctuations, investors often seek stocks that can withstand broader market pressures while offering potential for growth. Penny stocks, typically associated with smaller or newer companies, may appear outdated but remain a relevant investment area by presenting opportunities for growth at lower price points when backed by strong financial health and fundamentals.
Name
Share Price
Market Cap
Financial Health Rating
Foresight Group Holdings (LSE:FSG)
£4.91
£549.71M
★★★★★★
Warpaint London (AIM:W7L)
£2.10
£169.65M
★★★★★★
Ingenta (AIM:ING)
£0.755
£11.4M
★★★★★★
Integrated Diagnostics Holdings (LSE:IDHC)
$0.5225
$303.74M
★★★★★☆
RWS Holdings (AIM:RWS)
£0.942
£348.33M
★★★★★★
LSL Property Services (LSE:LSL)
£2.51
£257.82M
★★★★★☆
Alumasc Group (AIM:ALU)
£3.425
£123.16M
★★★★★★
Begbies Traynor Group (AIM:BEG)
£1.185
£188.66M
★★★★★★
Croma Security Solutions Group (AIM:CSSG)
£0.725
£9.98M
★★★★★★
Braemar (LSE:BMS)
£2.38
£72.51M
★★★★★★
Click here to see the full list of 287 stocks from our UK Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Concurrent Technologies Plc, with a market cap of £200.52 million, designs, develops, manufactures, and markets single board computers for system integrators and original equipment manufacturers.
Operations: The company generates revenue of £44.57 million from the design, manufacture, and supply of high-end embedded computer products.
Market Cap: £200.52M
Concurrent Technologies Plc, with a market cap of £200.52 million, has shown robust financial health and strategic growth in the tech sector. The company is debt-free, with short-term assets significantly exceeding liabilities. Recent earnings reports indicate stable revenue growth to £21.06 million for the half-year ended June 2025, alongside securing substantial contracts in both US and UK defense sectors worth millions of dollars. These contracts highlight Concurrent’s expanding role in providing high-performance computing solutions. Additionally, product innovations like the Apollo system and Bragi graphics card enhance its portfolio for demanding environments, supporting long-term sustainability and market presence.
Story Continues
AIM:CNC Financial Position Analysis as at Oct 2025
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Kitwave Group plc operates in the United Kingdom as a food and drink wholesaler, with a market cap of £193.43 million.
Operations: The company’s revenue is derived from three main segments: Ambient (£222.49 million), Foodservice (£298.67 million), and Frozen & Chilled (£246.87 million).
Market Cap: £193.43M
Kitwave Group plc, with a market cap of £193.43 million, operates as a food and drink wholesaler in the UK. The company is trading at 39.7% below its estimated fair value and has high-quality past earnings despite recent negative growth (-10.6%). Kitwave’s debt is well covered by operating cash flow (54.5%), though it carries a high net debt to equity ratio (54.1%). Its short-term assets exceed both short- and long-term liabilities, indicating solid liquidity management. Recent fiscal year-end changes aim to better align financial statements with business activities, potentially improving transparency for investors moving forward.
AIM:KITW Debt to Equity History and Analysis as at Oct 2025
Simply Wall St Financial Health Rating: ★★★★★★
Overview: NIOX Group Plc specializes in designing, developing, and commercializing medical devices for asthma diagnosis, monitoring, and management globally, with a market cap of £313.37 million.
Operations: The company generates revenue primarily from its NIOX® segment, which accounted for £46 million.
Market Cap: £313.37M
NIOX Group Plc, with a market cap of £313.37 million, is trading at 36% below its estimated fair value. Despite recent negative earnings growth of -55.5%, the company has demonstrated profitability over the past five years with an annual earnings growth rate of 54.2%. NIOX’s net profit margins have decreased to 10.7% from last year’s 28.2%, yet it remains debt-free and financially stable, with short-term assets exceeding liabilities significantly (£22.4M vs £6M). Recent half-year results show improved sales (£25.2 million) and net income (£5.9 million), indicating potential recovery in financial performance.
AIM:NIOX Revenue & Expenses Breakdown as at Oct 2025
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AIM:CNC AIM:KITW and AIM:NIOX.
This article was originally published by Simply Wall St.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com